



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.ngib.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO 2564	
10/611,741	07/01/2003	Adnan M.M. Mjalli	41305.287124		
7:	590 03/23/2004		EXAMINER		
Charles W. Calkins			BADIO, BARBARA P		
Kilpatrick Stockton LLP 1001 West Fourth Street			ART UNIT PAPER NUMB		
Winston-Salem, NC, 27101-2410			1616		

DATE MAILED: 03/23/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)					
		10/611,741 Examiner		MJALLI ET AL. Art Unit					
Office Action Sun	mary								
		Barbara P. B	adio, Ph.D.	1616					
The MAILING DATE of thi	s communication ap			e correspondence ad	ldress				
Period for Reply									
A SHORTENED STATUTORY I THE MAILING DATE OF THIS (o Edmissions of time may be available under after SIX (6) MONTHS from the mailing da If the portiod for reply seglified above is let If NO period for reply is specified above, it Failure to reply within the set or extended, Any reply received by the Office later than earned patent term adjustment. See 37 CI	the provisions of 37 CFR 1. the of this communication. It is than thirty (30) days, a repe maximum statutory period period for reply will, by statut three months after the mailing.	136(a). In no event, by within the statutor will apply and will ex-	however, may a reply be y minimum of thirty (30) o gire SIX (6) MONTHS for lon to become ABANDO	timely filed tays will be considered time om the mailing date of this of	ly. ommunication.				
Status									
1) Responsive to communic	ation(s) filed on								
2a) This action is FINAL.	2b)□ Thi	is action is non	-final.						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims									
4)⊠ Claim(s) <u>1,2,11-15,29,30</u> , 4a) Of the above claim(s) 5)□ Claim(s) is/are allo 6)□ Claim(s) is/are reje	is/are withdra wed. ected.								
7)		e subject to res	striction and/or ele	ection requirement.					
Application Papers									
9) ☐ The specification is object	ed to by the Examin	ier.							
10) The drawing(s) filed on	is/are: a) 🗌 ac	cepted or b)	objected to by th	e Examiner.					
Applicant may not request the	at any objection to the	e drawing(s) be	held in abeyance.	See 37 CFR 1.85(a).					
Replacement drawing sheet 11) The oath or declaration is		•							
Priority under 35 U.S.C. § 119									
12) Acknowledgment is made a) All b) Some col 1. Certified copies of 2. Copies of the certif application from the	None of: the priority documer the priority documer ied copies of the pri the international Burea	nts have been nts have been onty document au (PCT Rule	received. received in Applic Is have been rece 17.2(a)).	ation No vived in this National	Stage				
Attachment(s)									
Notice of References Cited (PTO-892))	4) Interview Summ						
Notice of Draftsperson's Patent Draw Information Disclosure Statement(s) (Paper No(s)/Mail Date			Paper No(s)/Mai) Notice of Information) Other:	I Date al Patent Application (PT	O-152)				

Page 2

Application/Control Number: 10/611,741

Art Unit: 1616

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-2 and 11-15, drawn to compounds and compositions, classified in class 564, subclass 123+.
 - II. Claims 29-30, drawn to a method for the inhibition of the interaction of RAGE with its physiological ligands, classified in class 514, subclass 610+
 - III. Claims 32-33(in part), drawn to a method for treating inflammation utilizing the compounds of formula I, classified in class 514, subclass 610+.
 - IV. Claims 32-33(in part), drawn to a method of treating vascular permeability utilizing the compounds of formula I, classified in class 514, subclass 610+.
 - Claims 32-33(in part), drawn to a method of treating nephropathy utilizing the compounds of formula I, classified in class 514, subclass 610+.
 - VI. Claims 32-33(in part), drawn to a method of treating atherosclerosis utilizing the compounds of formula I, classified in class 514, subclass 610+.
 - VII. Claims 32-33(in part), drawn to a method for treating retinopathy utilizing the compounds of formula I, classified in class 514, subclass 610+.

Art Unit: 1616

- VIII. Claims 32-33(in part), drawn to a method for treating Alzheimer utilizing the compounds of formula I, classified in class 514, subclass 610+.
- IX. Claims 32-33(in part), drawn to a method for treating erectile dysfunction utilizing the compounds of formula I, classified in class 514, subclass 610+.
- X. Claims 32-33(in part), drawn to a method for treating tumor utilizing the compounds of formula I, classified in class 514, subclass 610+.
- Claim 44, drawn to a process for preparing compounds of formula II, classified in class 564, subclass 123+.
- XII. Claim 45, drawn to a process for preparing compounds of formula III, classified in class 564, subclass 123+.
- XIII. Claim 46, drawn to a process for preparing compounds of formula IV, classified in class 564, subclass 123+.
- XIV. Claim 47, drawn to a process for preparing compounds of formula V, classified in class 564, subclass 123+.
- Claim 48, drawn to a process for preparing compounds of formula V, classified in class 564, subclass 123+.
- XVI. Claim 49, drawn to a process for preparing compounds of formula VI, classified in class 564, subclass 123+.
- XVII. Claim 50(in part), drawn to a process for preparing compounds of formula VII comprising reacting according to (a), classified in class 564, subclass 123+.

Page 4

Application/Control Number: 10/611,741

Art Unit: 1616

- XVIII. Claim 50(in part), drawn to a process for preparing compounds of formula

 VII comprising reacting according to (b), classified in class 564, subclass

 123+.
- XIX. Claim 50(in part), drawn to a process for preparing compounds of formula VII comprising reacting according to (c), classified in class 564, subclass 123+.
- Claim 51, drawn to a process for preparing compounds of formula VIII, classified in class 564, subclass 123+.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and II-X are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process for using the product as claimed can be practiced with another materially different product and the product as claimed can be used in a materially different process of using that product (see Inventions II-X).
- Inventions I and XI-XX are unrelated. Inventions XI-XX are drawn to processes
 of making compounds that differ in scope from those encompassed by Invention I.

Art Unit: 1616

 Inventions II-X (XI-XX) are unrelated. The different inventions are drawn to different processes of using (Inventions II-X) or making (Inventions XI-XX) the instantly claimed product.

- Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Groups II-XX, restriction for examination purposes as indicated is proper.
- Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from within the elected Group for search purposes, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

 Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1616

- 10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 11. The examiner has required restriction between product and process claims.

 Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not

Art Unit: 1616

commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Telephone Inquiry

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barbara P. Badio, Ph.D. whose telephone number is 571-272-0609. The examiner can normally be reached on M-F from 6:00am-3:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Darbaro Padis Barbara P. Badio, Ph.D. Primary Examiner Art Unit 1616

BB March 22, 2004